Genetically engineered cancer mouse models (GEMMs) enable in vivo tumor initiation by conditionally activating oncogenes or inactivating tumor suppressor genes in a tissue-specific and temporally controlled manner using Cre-loxP recombination systems, allowing modeling of endogenous tumor development within the native microenvironment. In the widely used conditional Kras model, a latent oncogenic Kras allele (LSL-Kras^G12D^) remains transcriptionally silenced until Cre recombinase excises a stop cassette, resulting in tissue-specific oncogene activation and subsequent tumor formation that recapitulates early tumor initiation and progression in vivo.
Transgenic/Knockout Models
Genetic engineering techniques are employed to precisely modify the genetic material of animals, thereby simulating human diseases or investigating the functions of specific genes in vivo. Strategies involving the permanent integration of exogenous genes into the animal genome are frequently used to model specific genetic disorders or to evaluate the biological effects of gene overexpression. Research into loss-of-gene-function focuses on gene knockout (KO) technology, which involves permanently inactivating a target gene to observe resulting changes in the animal's phenotype. Furthermore, this experiment provides an in-depth introduction to conditional gene knockout (such as the Cre-LoxP system), which enables precise control over gene knockout in specific tissues or at specific developmental stages, thereby effectively avoiding issues like embryonic lethality.
Related Experimental Schemes
The inducible CreER/CreERT2 system is based on a fusion between Cre recombinase and a modified estrogen receptor ligand-binding domain that retains Cre in the cytoplasm under basal conditions and allows nuclear translocation upon tamoxifen binding, enabling temporal control of site-specific recombination at loxP-flanked genomic loci in vivo or in vitro. Upon tamoxifen administration, CreER translocates to the nucleus and catalyzes recombination between loxP sites, resulting in excision or inversion of floxed DNA segments and enabling temporally defined gene knockout in specific tissues depending on promoter-driven CreER expression. This system has been widely used for inducible gene deletion and lineage tracing in mice, including validation of efficient temporal recombination in developmental and adult tissues using tamoxifen induction paradigms.
The Cre-lox conditional knockout system is a site-specific recombination technology in which Cre recombinase recognizes loxP sites flanking a genomic sequence, enabling excision, inversion, or rearrangement of the intervening DNA in a spatially and/or temporally controlled manner, allowing tissue-specific gene inactivation in vivo when Cre is expressed under defined promoters. This system is widely used to overcome limitations of conventional germline knockouts, particularly embryonic lethality or systemic effects that obscure tissue-specific gene function, by restricting recombination to selected cell types or developmental stages. Cre-mediated recombination efficiency and specificity depend on factors such as Cre driver expression pattern, loxP configuration, and genomic context, which can lead to mosaic recombination and variable knockout outcomes. The system is typically validated using reporter alleles or floxed target genes to confirm recombination at DNA and protein levels.
CRISPR/Cas9-mediated knock-in of point mutations in animal models relies on RNA-guided endonuclease activity to generate site-specific DNA double-strand breaks (DSBs), which are subsequently repaired by endogenous cellular pathways, predominantly non-homologous end joining (NHEJ) or homology-directed repair (HDR). Precise nucleotide substitutions or small edits are introduced when an exogenous donor template (e. g. , single-stranded oligodeoxynucleotide or double-stranded DNA) is used to bias repair toward HDR, enabling defined point mutations at the target locus in embryos or embryonic stem cells. HDR-mediated knock-in is generally less efficient than NHEJ-mediated indel formation, which has driven the development of strategies such as donor template optimization, cell cycle considerations, and chemical enhancement of HDR to improve precise genome editing outcomes in mammalian systems and animal models.
Transgenic overexpression models are generated by introducing an exogenous DNA construct containing a gene of interest into the germline or early embryo so that the transgene integrates into the host genome and is stably expressed under the control of a chosen promoter, enabling in vivo analysis of gene function and disease mechanisms. The most established strategy is pronuclear microinjection of linearized DNA into fertilized oocytes, followed by random genomic integration and germline transmission, which allows constitutive or tissue-specific overexpression depending on promoter selection. Alternative strategies include viral vector-mediated gene delivery (e. g. , lentiviral systems) and transposon-based integration systems, which improve efficiency of stable genomic insertion in certain contexts. These approaches collectively enable functional gain-of-function studies in vivo across multiple organ systems and disease models.
Constitutive germline knockout models are generated by producing a heritable loss-of-function allele in the mouse genome, typically through complete gene disruption in embryonic stem (ES) cells followed by germline transmission or through CRISPR/Cas-mediated editing of zygotes, resulting in offspring that carry a stable null allele in all tissues. Classical approaches rely on homologous recombination in ES cells to introduce targeted gene disruptions, which are then transmitted through chimeric mice to the germline. More recent genome editing strategies use CRISPR/Cas systems to induce double-strand breaks and non-homologous end joining (NHEJ), frequently generating frameshift mutations that abolish gene function, enabling faster generation of knockout alleles directly in embryos. Germline transmission or direct germline editing ensures that the mutation is present in all cells of the resulting animal, allowing systemic functional analysis of gene loss.
The Rosa26 locus is widely used as a genomic \"safe harbor\" site because it supports stable and ubiquitous transgene expression without overt disruption of endogenous organismal development, enabling consistent reporter or functional gene expression across tissues in multiple mammalian species. Reporter knock-in models at Rosa26 are typically generated by inserting a transgene cassette (e. g. , fluorescent proteins or Cre-dependent reporters) into the locus using either CRISPR/Cas9-mediated homology-directed repair in zygotes or homologous recombination in embryonic stem cells, resulting in germline-transmissible alleles. After correct integration, reporter expression is driven by inserted regulatory elements (commonly ubiquitous promoters such as CAG or endogenous Rosa26 regulatory context), allowing visualization of gene expression patterns or lineage tracing through fluorescence or recombinase-dependent activation. These models function as readouts of genome editing efficiency and
CRISPR/Cas9 knockout animal modeling uses guide RNA to direct Cas9 to a genomic target, where Cas9 creates a DNA double-strand break; repair by error-prone non-homologous end joining generates insertions or deletions that can disrupt coding sequence and produce knockout alleles. Classic animal-model workflows deliver Cas9 mRNA or Cas9 protein with sgRNA into fertilized zygotes by microinjection or electroporation, then transfer edited embryos into pseudopregnant recipients and genotype founders for target-site mutations.
Cre-lox lineage tracing labels cells that express Cre recombinase by excising a loxP-flanked STOP cassette in a reporter allele, causing permanent reporter expression in the recombined cell and its descendants. Inducible CreERT2 models add temporal control because tamoxifen activates CreERT2-dependent recombination, allowing cells expressing a selected promoter at a chosen time point to be fate-mapped during development, homeostasis, injury, or disease. Reporter readouts include β-galactosidase, EYFP/ECFP, tdTomato, membrane GFP, and multicolor fluorescent proteins; these readouts detect recombined cells by histology, fluorescence microscopy, flow cytometry, or tissue imaging.
